Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Jul;52(1):196-204.
doi: 10.1111/apt.15741. Epub 2020 May 26.

Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase

Han Ah Lee  1 , Hyun Woong Lee  2 , In Hee Kim  3 , Soo Young Park  4 , Dong Hyun Sinn  5 , Jung Hwan Yu  6 , Yeon Seok Seo  1 , Soon Ho Um  1 , Jung Il Lee  2 , Kwan Sik Lee  2 , Chang Hun Lee  3 , Won Young Tak  4 , Young Oh Kweon  4 , Wonseok Kang  5 , Yong-Han Paik  5 , Jin-Woo Lee  6 , Sang Jun Suh  7 , Young Kul Jung  7 , Beom Kyung Kim  8   9 , Jun Yong Park  8   9 , Do Young Kim  8   9 , Sang Hoon Ahn  8   9 , Kwang-Hyub Han  8   9 , Hyung Joon Yim  7 , Seung Up Kim  8   9
Affiliations
Multicenter Study

Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase

Han Ah Lee et al. Aliment Pharmacol Ther. 2020 Jul.

Abstract

Background: Anti-viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune-tolerant phase.

Aims: To investigate the cumulative incidence of phase change and hepatocellular carcinoma (HCC) and independent predictors for phase change in patients with CHB in immune-tolerant phase.

Methods: In total, 946 patients in immune-tolerant phase, defined as hepatitis B e antigen positivity, HBV-DNA >20 000 IU/mL and alanine aminotransferase (ALT) ≤40 IU/L, between 1989 and 2017 were enrolled from eight institutes.

Results: The mean age of study population (429 men and 517 women) was 36.7 years. The mean ALT and HBV-DNA levels were 24.6 IU/L and 8.50 log10 IU/mL, respectively. Of the study population, 476 (50.3%) patients remained in immune-tolerant phase throughout the study period (median: 63.6 months). The cumulative incidence rates of phase change and HCC at 10 years were 70.7% and 1.7%, respectively. Multivariate analyses revealed that HBV-DNA level >107 IU/mL was associated independently with a reduced risk of phase change (hazard ratio [HR] = 0.734, P = 0.008), whereas a high ALT level, above the cut-off recommended in the Korean Association for the Study of the Liver guidelines (34 IU/L for men and 30 IU/L for women), was associated independently with a greater risk of phase change (HR = 1.885, P < 0.001).

Conclusions: The criterion of HBV-DNA level > 107 IU/mL may be useful to define immune-tolerant phase. In addition, an extremely low risk of HCC development was observed in patients with CHB in immune-tolerant phase.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther. 2011;16:1169-1186.
    1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
    1. Iloeje UH, Yang H, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
    1. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017:370-398.
    1. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25:93-159.

Publication types

MeSH terms

LinkOut - more resources